The Journal of Allergy and Clinical Immunology
Volume 124, Issue 5 , Pages 873-880, November 2009

Management of chronic obstructive pulmonary disease: Moving beyond the asthma algorithm

  • Erin Gordon, MD

      Affiliations

    • Division of Pulmonary and Critical Care Medicine, University of California, San Francisco, Calif
  • ,
  • Stephen C. Lazarus, MD

      Affiliations

    • Division of Pulmonary and Critical Care Medicine, University of California, San Francisco, Calif
    • Cardiovascular Research Institute, University of California, San Francisco, Calif
    • Corresponding Author InformationReprint requests: Stephen C. Lazarus, MD, Division of Pulmonary and Critical Care Medicine, University of California, San Francisco, 505 Parnassus Ave, M-1083, San Francisco, CA 94143-0111.

Received 15 July 2009; received in revised form 24 September 2009; accepted 25 September 2009.

For many years, chronic obstructive pulmonary disease (COPD) was considered a disease of fixed airflow obstruction for which there was no good treatment. Out of desperation and frustration, health care providers extrapolated from asthma to COPD, and standard asthma therapy was adopted without evidence for efficacy. In recent years, we have gained a better understanding of the pathophysiologic differences between asthma and COPD, and prospective controlled trials have provided a rationale for therapy. Smoking cessation is critically important, both as primary prevention and as an effective way to slow the decrease in lung function in patients with established disease. β2-Adrenergic and anticholinergic agonists improve lung function and relieve symptoms in most patients. Tiotropium improves exercise tolerance and quality of life and reduces exacerbations and hospitalizations. The increase in lung function seen with tiotropium is sustained with continued use over at least 3 to 4 years. Inhaled corticosteroids decrease exacerbations and improve quality of life, and their effect seems greatest in patients with lower lung function and in exacerbation-prone patients. There is no evidence that inhaled corticosteroids alone affect mortality, despite the reduction in exacerbations and increased risk of pneumonia. In some patient populations, inhaled fluticasone, salmeterol, or the combination might slow the rate of loss of lung function.

Rather than reflexively using effective asthma therapy in the patient with COPD, current and future therapy for COPD is increasingly evidence based and targeted to specific inflammatory pathways that are important in patients with COPD.

Key words: Chronic obstructive pulmonary disease, asthma, airflow obstruction, inhaled corticosteroids, oral corticosteroids, bronchodilators, long-acting bronchodilators, β2-agonists, anticholinergics, mucolytics, antioxidants, pulmonary rehabilitation, home oxygen, smoking cessation, immunization

Abbreviations used: COPD, Chronic obstructive pulmonary disease, FVC, Forced vital capacity, ISOLDE, Inhaled Steroids in Obstructive Lung Disease, OR, Odds ratio, TORCH, Towards a Revolution in COPD Health

 

 Series editors: Donald Y. M. Leung, MD, PhD, and Dennis K. Ledford, MD

PII: S0091-6749(09)01459-6

doi:10.1016/j.jaci.2009.09.040

The Journal of Allergy and Clinical Immunology
Volume 124, Issue 5 , Pages 873-880, November 2009